Global

Outgoing EMA Director Thomas Lonngren discusses a decade at the helm of Europe's top regulatory office

Cegedim survey documents whether European industry is ready for the challenge of new compliance and disclosure risks on promotional spend

November 6, 2010.

With all the money and momentum focused on medicines in emerging markets, it may be time to take a closer look at business opportunities in this more familiar neighbor to the East

A European pilot initiative will test the impact of consultations with a number of stakeholders such as patient representatives and payers on early stage drug development.

As part of a team, you will prepare meetings of European Pharmacopoeia groups of experts, contribute to the preparation of working documents for these groups, contribute to the elaboration and revision of European Pharmacopoeia texts and follow up meetings with a view to publication of scientific texts and memoranda.

A report by the European Commission aimed at exploring patent exploitation by Big Pharma winds up generating more angst than answers

September 21, 2010.

Anjan Selz offers a Strengths, Weaknesses, Opportunities and Threats analysis of the biosimilars market.

September 08, 2010.

Dr Frank Floether provides a no-nonsense guide to securing a successful alliance in Asia.

August 20, 2010.

13 August, 2010.

The European Generic Medicines Association's Director for Scientific Affairs, Suzette Cox, talks to us about the environment for biosimilars.

With substantial growth predicted in the life sciences industry, appointing the right General Manager (GM) in China has never been more important. But where should he or she come from?

It's back to the future in Pharm Exec's second-annual review of industry prospects in the IMS "Pharmerging 17"

August 2, 2010.

August 01, 2010. French pharma giant accused of providing "misleading" and "incorrect" information.

July 23, 2010.

July 23, 2010.

July 14, 2010.

July 10, 2010.

Kamal Biswas outlines some techniques for the successful design and implementation of an IT shared services model in pharma.

As Europe sets the pace in slashing drug prices to meet austerity goals industry is seeking fresh ways to control the fallout. Will more dialogue be enough?

As they build market share, companies need a plan to limit exposure to steep fines and executive prosecutions.